CA9 and renal cell carcinoma: CAIX-specific CARNK92 at an effector: target (E:T) ratio of 30:1 induced specific cell lysis varying from 25-55% for different RCC cell lines, with an unobtrusive 10% increase when CAIX-specific CARNK92 was combined with bortezomib, a proteasome inhibitor [34].